Stocks · News reference
Bernstein Research has updated its outlook on Novo Nordisk, raising the price target while maintaining an 'Underperform' rating.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Eli Lilly has entered an agreement with telehealth platform Hims & Hers Health to offer its obesity medications Zepbound and Foundayo directly on the platform, intensifying competition with Novo Nordisk's existing presence on the site.
The Ozempic market is projected to grow from USD 30.04 billion in 2026 to USD 113.95 billion by 2032, with a CAGR of 24.89%. Growth is driven by expanding diabetes treatment demand, broader metabolic health applications, and increasing adoption of GLP-1 therapies. North America leads the market, while Asia-Pacific emerges as a significant growth region. Key challenges include treatment affordability, reimbursement restrictions, and supply-chain requirements.
Novo Nordisk has published a mandatory disclosure regarding share transactions conducted by its board members, executives, and their associated persons.
Goldman Sachs has increased its price target for Novo Nordisk shares from 290 to 304 Danish kroner while maintaining a 'Neutral' rating.
Novo Nordisk has named Galderma Group CFO Luigi La Corte as its new finance chief.
Viking Therapeutics is trading 23% below its recent $35 secondary offering price after raising $575 million for phase 3 development of its weight loss drug VK2735. Despite the post-offering stock decline due to dilution concerns, the article argues this presents a buying opportunity for patient investors, as Viking is advancing dual GLP-1/GIP receptor agonist candidates in injectable and oral formats while the weight loss drug market is projected to reach nearly $100 billion by decade's end.